FDA approvals are critical milestones for medical device companies, often leading to increased product adoption and sales. This approval expands Boston Scientific's cardiovascular treatment options, likely enhancing its competitive edge and attractiveness to investors. The direct impact on BSX stock is expected to be positive in the short term, as the market reacts to the expansion of the company's product portfolio and its potential to capture more of the coronary treatment market.